DORAs, which target the orexin signaling pathway, are involved in sleep–wake regulation and have the potential to effectively treat insomnia with fewer next-day residual effects than other sleep-promoting drugs with different mechanisms of action. The gene discussed is HCRT; the disease is insomnia.